Extrafine triple therapy in patients with asthma and persistent airflow limitation

Dave Singh, Johann Christian Virchow, Giorgio Walter Canonica, Andrea Vele, Maxim Kots, George Georges, Alberto Papi

Source: Eur Respir J, 56 (3) 2000476; 10.1183/13993003.00476-2020
Journal Issue: September
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Dave Singh, Johann Christian Virchow, Giorgio Walter Canonica, Andrea Vele, Maxim Kots, George Georges, Alberto Papi. Extrafine triple therapy in patients with asthma and persistent airflow limitation. Eur Respir J, 56 (3) 2000476; 10.1183/13993003.00476-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Bronchodilator reversibility is associated with non-adherence to inhalers in stable asthma patients, without airflow limitation.
Source: Virtual Congress 2020 – Lung function diagnostics
Year: 2020


Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation
Source: Eur Respir J, 53 (5) 1900235; 10.1183/13993003.00235-2019
Year: 2019



Once-daily tiotropium Respimat add-on therapy improves lung function in children with moderate symptomatic asthma, independent of the degree of airflow obstruction
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017


Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


Withdrawal of high-dose inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: a feasibility study in primary care.
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019

Withdrawal of inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: who is suitable for a trial of withdrawal?
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019

Influence of combined antiasthmatic basic therapy on hyperinflation in patients with severe bronchial asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 553s
Year: 2007

Impacts of bronchiectasis in asthma patients with airflow limitation
Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease
Year: 2020


Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005

The effectiveness of nebulizer therapy in the treatment of patients with bronchial asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 424s
Year: 2001

Effect of montelukast on excessive airway narrowing in adult asthmatics not on controller therapy
Source: Annual Congress 2006 - New developments in the treatment and management of asthma
Year: 2006


Deprescribing of inhaled corticosteroids in patients with COPD with mild or moderate airflow limitation: what do patients think?
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019

A new budesonide/formoterol inhalation therapy in patients with asthma, COPD and ACOS
Source: International Congress 2017 – Bronchial asthma management
Year: 2017

Targeting therapy to the site of airflow limitation in COPD
Source: International Congress 2019 – Putting COPD patient needs first: Time for optimizing treatment and device selection
Year: 2019

The effect of inhaler switching on asthma and COPD patients
Source: International Congress 2018 – Respiratory epidemiology: from COPD to factors that associate with lung function and infections
Year: 2018



Intermittent therapy with budesonide/formoterol in children with moderate asthma.
Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities
Year: 2017


Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019



Longitudinal change in bronchial responsiveness in patients with cough variant asthma and the effect of inhaled corticosteroids
Source: Eur Respir J 2004; 24: Suppl. 48, 587s
Year: 2004